Methods: A retrospective review was completed for 232 patients with MH. Sixty-six patients elected to proceed with diagnostic Botox injections. Of these, 24 continued long-term therapeutic Botox injections while 42 matriculated to surgery. Outcomes were tracked.
Results: Therapeutic long-term trigger site-directed Botox injection resulted in significant improvement in migraine headache index (MHI) (53.5+/-83.0, p<0.006), headache days/month (9.2+/-12.7, p<0.0009) and migraine severity (2.6+/-2.5, p<0.00008) versus baseline. MHI improved from the initiation of diagnostic injections to the establishment of steady-state injections (p<0.002), and further improved over time (p<0.05, mean follow-up 615 days) with no desensitization observed. Decompressive surgery resulted in significant improvement in MHI (100.8+/-109.7, p<0.0000005), headache days/month (10.8+/-12.7, p<0.000002), migraine severity (3.0 +/- 3.8, p<0.00001), and migraine duration in hours (16.8+/-21.6, p<0.0007). MHI improvement with surgery was better than long-term Botox injection (p<0.05).
Conclusions: Though inferior to surgical decompression, anatomically-directed therapeutic trigger site Botox injection is an effective therapy for MH as an alternative to non-site-directed Botox injection with decreased dosage requirements and the potential for decreased cost.